toxylact: a07ab02 phthalylsulfathiazole

The first professional lActological database in the word

Phthalylsulfathiazole (ATC A07AB02) is a locally acting intestinal sulfonamide antibacterial used orally for dysentery, colitis, gastroenteritis and preoperative intestinal decontamination, with action largely confined to the gut lumen. Because it is only slightly absorbed from the gastrointestinal tract and systemic exposure is very low, transfer into breast milk is expected to be minimal and available lactation resources classify it as compatible with breastfeeding, with routine clinical follow‑up.atcddd.fhi+5

Pharmacological class and indications

Phthalylsulfathiazole is a broad‑spectrum sulfonamide antimicrobial classified in ATC subgroup A07AB “Intestinal sulfonamides,” indicated mainly for intestinal infections such as bacillary dysentery, colitis, gastroenteritis, and for preoperative preparation in intestinal surgery. It has also been used in veterinary medicine for diarrhea and enteritis in several animal species, reflecting its targeted activity within the gastrointestinal tract.atcddd.fhi+3

Mechanism of action

Like other sulfonamides, phthalylsulfathiazole acts as a folic acid synthesis inhibitor by competitively antagonizing para‑aminobenzoic acid (PABA) and inhibiting dihydropteroate synthase. This blockade of dihydrofolic acid synthesis impairs bacterial production of purines and pyrimidines, leading to broad‑spectrum bacteriostatic activity against many gram‑positive and gram‑negative intestinal pathogens.drugbank+5

Pharmacokinetics relevant to lactation

Phthalylsulfathiazole is poorly absorbed after oral administration and remains mainly in the intestinal lumen; only about 5% of the ingested dose is absorbed as the active metabolite sulfathiazole and eliminated in urine. The drug is therefore considered to exert primarily local intestinal effects with little or no systemic impact, which implies very low maternal plasma concentrations and, consequently, low potential for significant transfer into human milk.atcddd.fhi+4

Maternal toxicity and adverse effects

Because systemic absorption is minimal, phthalylsulfathiazole produces few systemic adverse effects at usual therapeutic doses, and the risk of classic sulfonamide renal complications such as crystalluria is very low. Reported adverse reactions include gastrointestinal upset (nausea, vomiting), hypersensitivity reactions (skin rash), vitamin B deficiency, agranulocytosis and, rarely, aplastic anemia, so monitoring for allergic or hematologic signs is advisable during longer courses.drugs.ncats+4

Excretion into breast milk

Specific measurements of phthalylsulfathiazole levels in human milk are not available, but its pharmacokinetic profile (very low systemic absorption and predominantly local intestinal action) indicates that milk concentrations, if present, should be low. Lactation reference sources describe the drug as remaining mainly unabsorbed in the intestine, with only a small fraction (approximately 5%) absorbed as sulfathiazole, and classify it as “compatible” and “not risky for breastfeeding or infant,” while still recommending clinical follow‑up.drugs+3

Reported effects in breastfed infants

There are no published case reports directly linking phthalylsulfathiazole exposure via breast milk to adverse outcomes in breastfed infants. Extrapolating from broader sulfonamide data, systematic reviews of agents such as sulfamethoxazole have not identified cases of neonatal kernicterus attributable to breastfeeding exposure in healthy full‑term infants beyond the immediate newborn period, although theoretical risks remain for vulnerable infants.who+2

Impact on lactation and breast milk

No evidence suggests that phthalylsulfathiazole reduces milk production or alters lactation physiology. As with other antibiotics, potential indirect effects include changes in maternal and infant gut microbiota and the antibiotic resistome, but these are general concerns with antimicrobial use rather than specific to this agent.nature+3

Clinical use in breastfeeding

Given its minimal systemic absorption and localized intestinal action, phthalylsulfathiazole is considered a low‑risk option for breastfeeding women when an intestinal sulfonamide is clinically indicated and alternative agents are unsuitable. Nevertheless, standard sulfonamide precautions apply: avoid or use with particular caution in mothers of premature, jaundiced, ill or G6PD‑deficient infants, especially during the early neonatal period, when theoretical risks of bilirubin displacement and hemolysis are greatest.atcddd.fhi+5

Infant monitoring recommendations

When phthalylsulfathiazole is used during breastfeeding, routine infant monitoring should include observation for jaundice, poor feeding, lethargy, or signs of hemolysis (pallor, dark urine), particularly in young or high‑risk infants. For older, healthy, full‑term infants, practical monitoring focuses on gastrointestinal disturbances (diarrhea, vomiting) and oral or diaper candidiasis, similar to other antibiotics used during breastfeeding.who+3

Risk–benefit assessment

For mothers with significant intestinal infections where phthalylsulfathiazole is an appropriate therapeutic choice, the benefits of effective treatment and of continuing breastfeeding will often outweigh the small, theoretical risks of infant exposure via milk. In settings where other antibiotics with extensive lactation safety data are suitable, these may be preferred for neonates and high‑risk infants, but phthalylsulfathiazole remains a reasonable option in healthy, full‑term infants beyond the early newborn period when clinically indicated.atcddd.fhi+5

Key counselling points

Healthcare professionals should explain that phthalylsulfathiazole is a locally acting intestinal sulfonamide that is poorly absorbed, leading to very low maternal blood levels and correspondingly low expected transfer into breast milk. Mothers should be encouraged to continue breastfeeding when treatment is necessary, while observing their infants for jaundice or gastrointestinal symptoms and promptly seeking medical advice if such signs develop, especially in neonates or medically vulnerable infants.who+5

Recent ARTICLES

July 24

Abdominal Compartment Syndrome

PWhile the formal term and its consensus definitions were codified by the World Society of the Abdominal Compartment Syndrome (WSACS) only in the early 2000s, the physiological underpinnings have been observed for over 150 years. In 1863, the French physiologist Etienne-Jules Marey was the first to document the reciprocal relationship between intra-abdominal pressure (IAP) and respiratory function, noting that the expansion of the abdominal cavity directly impacted the efficiency of the thoracic bellows.

July 18

Assessment of Postoperative Fever

For the physician and the student of medicine, the assessment of postoperative fever is not merely a task of temperature monitoring, but a diagnostic journey that requires a nuanced understanding of immunology, physiology, and clinical timing. Guided by the principle of "Primum non nocere," this report seeks to bridge the gap between complex pathophysiological mechanisms and the empathetic care of the patient, providing a comprehensive framework for identifying, understanding, and managing this common clinical challenge.

July 14

Clinical Review of Congenital and Acquired Cystic Kidney Diseases

The healing arts, as envisioned by the ancient traditions of medicine, seek not merely the eradication of pathology but the restoration of a delicate equilibrium between the body’s internal environment and the external world. In the realm of nephrology, cystic diseases of the kidney represent a profound disruption of this balance.

Spotlight

A Comprehensive Analysis of Complement System Deficiencies in Pediatric and Adult Populations

The human immune system is a tapestry of ancient evolutionary mechanisms and highly specialized adaptive responses, woven together to maintain the delicate equilibrium of health. At the heart of this architecture lies the complement system, a complex network of over fifty proteins that function as the primordial vanguard of innate immunity. Named for its ability to "complement" the action of antibodies, this system serves as a bridge between the immediate, non-specific recognition of pathogens and the targeted, long-term memory of the adaptive immune response. However, when this sentinel falls silent due to genetic or acquired deficiencies, the result is a state of nuanced immunosuppression that significantly alters the human clinical landscape across all ages.